Google
RNA — ATRIUM THERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
RNA FAQ
What is RNA's ROE?
ATRIUM THERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -169.35%.
What is RNA's dividend yield?
ATRIUM THERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is RNA's Deepscope Quality Score?
Deepscope rates RNA's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RNA?
Deepscope's AI Timing Score for RNA is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RNA belong to?
ATRIUM THERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 11.80
Price
-0.50
(-4.07%)
Day Change
|
|
|---|
RNA, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 11.80 |
| PBV / Sector |
0.86 / 4.63
GREAT
|
| Earning Per Share | -23.18 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
2.52 M
GREAT
|
| Average 1W Daily Value |
2.14 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
54% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:01 |
| Symbol | RNA |
| Name | ATRIUM THERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 17.11 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 201.85 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10578 Science Center Drive, San Diego, CA, United States, 92121
Phone: 619 876 0700
Website: https://atriumtherapeutics.com
Employees: 511
Sector: Healthcare >> Biotechnology
Description: Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
